Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours

Fig. 3

SLC7A5 mRNA expression and its association with clinicopathological parameters and molecular subtypes. a SLC7A5 and tumour size. b SLC7A5 and tumour grade. c SLC7A5 and lymph node stage. d SLC7A5 and Nottingham Prognostic Index. e SLC7A5 and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) integrative clusters. f SLC7A5 and prediction analysis of microarray 50 (PAM50) subtypes, g SLC7A5 and SMCGENE subtypes in the METABRIC cohort using one-way analysis of variance with the post-hoc Tukey test

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us